Previous close | 0.00 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 1.11 |
PE ratio (TTM) | 14.86 |
EPS (TTM) | 0.96 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Oslo, Norway, 17th of February 2023 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the fourth quarter 2022 Det company enjoyed a very strong finishing quarter in 2022 with a 42% revenue and other income growth compared to last year. Revenue and other income in the fourth quarter ended at MNOK 111 compared to MNOK 78 in Q4 2021. Sales volume in the quarter was up by 11%. In addition, Vistin received a liquidated damage (LD) compensation of MNOK 13 in rela
Oslo, Norway, 10 February 2023 Vistin Pharma ASA will release its fourth quarter and preliminary 2022 results on Friday 17th of February 2023. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Friday 17th of February at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The fourth quarter conference call will be available via web and audio through the following access points
Oslo, Norway, 9 December 2022 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) announces that it has entered into a long-term industrial energy agreement with Statkraft, the leading Norwegian energy supplier. The agreement will secure a significant part of Vistin’s electricity demand on competitive terms until 2032. The agreement includes Guarantees of Origin as certification of the renewable energy supply, and starts 1.1.2023. 2022 has been very challenging for Vistin and the Norwegian industry,